LL&M Scientific Co-Chair

Ruben Niesvizky

MD
Professor of Medicine
Weill Cornell Medicine/NewYork-Presbyterian Hospital

Ruben Niesvizky, MD is Director of the Multiple Myeloma Center and Director of Oncology Operations at Weill Cornell Medicine/New York-Presbyterian Hospital. He is Professor of Medicine at Weill Cornell Medical College and Attending Physician at the New York-Presbyterian Hospital.

Dr. Niesvizky received his medical degree from the National Autonomous University of Mexico, Mexico City. He completed a residency in internal medicine and a research fellowship in cell biology/granulomonopoiesis at the National Institute of Medical Sciences and Nutrition in Mexico City. Dr. Niesvizky served as Chief Fellow during his training as a clinical hematology fellow at Mt. Sinai Medical Center, New York. He trained as a hematology/oncology fellow at Memorial Sloan-Kettering Cancer Center, New York, where he was assistant attending physician for 6 years. Dr. Niesvizky is fluent in Spanish, Hebrew and English.

Dr. Niesvizky’s work has been published in the New England Journal of Medicine, Blood, JCO, Leukemia and Lymphoma, and Seminars in Oncology. He was the director of the clinical core of the Specialized Center of Research (SCOR) of the Leukemia and Lymphoma Society granted in 2000. He is the recipient of various grants and awards from the National Cancer Institute; a K23 award and 3 translational research grants for the development of new drugs. Dr Niesvizky regularly presents at annual meetings such as ASH and ASCO, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

2027 Sessions

Q&A Panel

Moderator

Panelist

Sunday, February 07 3:25–3:35 PM
Room King Ballroom 3
LL&M Scientific Co-Chair

Ruben Niesvizky

MD
Professor of Medicine
Weill Cornell Medicine/NewYork-Presbyterian Hospital

Ruben Niesvizky, MD is Director of the Multiple Myeloma Center and Director of Oncology Operations at Weill Cornell Medicine/New York-Presbyterian Hospital. He is Professor of Medicine at Weill Cornell Medical College and Attending Physician at the New York-Presbyterian Hospital.

Dr. Niesvizky received his medical degree from the National Autonomous University of Mexico, Mexico City. He completed a residency in internal medicine and a research fellowship in cell biology/granulomonopoiesis at the National Institute of Medical Sciences and Nutrition in Mexico City. Dr. Niesvizky served as Chief Fellow during his training as a clinical hematology fellow at Mt. Sinai Medical Center, New York. He trained as a hematology/oncology fellow at Memorial Sloan-Kettering Cancer Center, New York, where he was assistant attending physician for 6 years. Dr. Niesvizky is fluent in Spanish, Hebrew and English.

Dr. Niesvizky’s work has been published in the New England Journal of Medicine, Blood, JCO, Leukemia and Lymphoma, and Seminars in Oncology. He was the director of the clinical core of the Specialized Center of Research (SCOR) of the Leukemia and Lymphoma Society granted in 2000. He is the recipient of various grants and awards from the National Cancer Institute; a K23 award and 3 translational research grants for the development of new drugs. Dr Niesvizky regularly presents at annual meetings such as ASH and ASCO, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

Faculty

Melissa Alsina

MD
Head, Myeloma Section
H.Lee Moffitt Cancer Center

Dr. Melissa Alsina is Professor of Medicine in the Blood and Marrow Transplant Program at Moffitt Cancer Center and Head of the Multiple Myeloma Transplant Program. A specialist in multiple myeloma and bone marrow transplantation, Dr. Alsina focuses much of her clinical research on novel therapies in myeloma, including immunotherapies. A graduate of the University of Puerto Rico School of Medicine, Dr. Alsina completed her residency in Medicine at San Juan Veterans Administration Hospital, followed by a fellowship in Hematology at San Juan City Hospital in Puerto Rico and Medical Oncology/Hematology at the University of Texas Health Science Center at San Antonio, Texas. Before coming to Moffitt in 2000, Dr. Alsina was an Assistant Professor of Medicine at the South Texas Veterans Health Care System in San Antonio. She was also co-director of the Myeloma Bone Disease Program Clinic at the UT Health Science Center at San Antonio, where she served on the faculty from 1995-1999. Dr. Alsina is a member of several professional organizations, including the International Myeloma Society and The American Society of Hematology, and has been a member of the NCCN myeloma panel and the NCI Myeloma Steering Committee. She is also very active in organizing educational programs for myeloma patients and their families.

Faculty

Adriana Rossi

MD
Director of Myeloma CAR-T and Stem Cell Transplant Clinical Program
Mount Sinai School of Medicine

Adriana Rossi is the Director of Myeloma CAR-T and Stem Cell Transplant Clinical Program at the Center of Excellence for Multiple Myeloma at the Mount Sinai School of Medicine. Dr Rossi has extensive experience in treating patients with multiple myeloma and related diseases, with special focus on cellular therapy.

Faculty

Ken Shain

From Trial to Treatment: A Case Discussion Panel in Myeloma

Moderator

Panelist

Sunday, February 07 3:35–4:25 PM
Room King Ballroom 3
Miami Regional Co-Chair

Ola Landgren

MD, PhD
Professor of Medicine, Chief of Myeloma Division & Institute
Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami

C. Ola Landgren is an MD/PhD Hematology/Oncology specialist with almost 30 years of leadership experience in translational cancer medicine. Over the past two decades, he has served as the leader for large programs at the National Cancer Institute/National Institutes of Health (NCI/NIH), Memorial Sloan Kettering Cancer Center (MSKCC), and University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC). Currently, he is a Professor of Medicine, Leader of the Translational & Clinical Oncology program, Chief of the Division of Myeloma, and Director of the Myeloma Research Institute at UM/SCCC. Before joining UM/SCCC in 2020, he served as Chief of the Myeloma Service at MSKCC and was Professor Medicine at Cornell Medical College from 2014 to 2020. Prior to that, he served as Senior Investigator and Chief of the Multiple Myeloma Section at the Intramural Program of the NCI/NIH from 2004 to 2014. Prior to joining NCI/NIH, he earned his MD and PhD at Karolinska Institute in Stockholm, Sweden. Throughout his career, his clinical and scientific focus has been on the development of novel treatment strategies for patients with myeloma, partnered with molecular profiling and development of technologies for minimal residual disease (MRD) assessment: targeted detection/intervention to prevent, find, and treat. He has published over 450 peer-reviewed articles in high-impact journals, including Nature Communications, Nature Medicine, Blood, Lancet, JAMA, JCO, and New England Journal of Medicine. Numerous times, he has chaired sessions and presented data at international conferences including ASH, EHA, and ASCO. He is a member of American Society of Clinical Investigation (ASCI).

LL&M Scientific Co-Chair

Ruben Niesvizky

MD
Professor of Medicine
Weill Cornell Medicine/NewYork-Presbyterian Hospital

Ruben Niesvizky, MD is Director of the Multiple Myeloma Center and Director of Oncology Operations at Weill Cornell Medicine/New York-Presbyterian Hospital. He is Professor of Medicine at Weill Cornell Medical College and Attending Physician at the New York-Presbyterian Hospital.

Dr. Niesvizky received his medical degree from the National Autonomous University of Mexico, Mexico City. He completed a residency in internal medicine and a research fellowship in cell biology/granulomonopoiesis at the National Institute of Medical Sciences and Nutrition in Mexico City. Dr. Niesvizky served as Chief Fellow during his training as a clinical hematology fellow at Mt. Sinai Medical Center, New York. He trained as a hematology/oncology fellow at Memorial Sloan-Kettering Cancer Center, New York, where he was assistant attending physician for 6 years. Dr. Niesvizky is fluent in Spanish, Hebrew and English.

Dr. Niesvizky’s work has been published in the New England Journal of Medicine, Blood, JCO, Leukemia and Lymphoma, and Seminars in Oncology. He was the director of the clinical core of the Specialized Center of Research (SCOR) of the Leukemia and Lymphoma Society granted in 2000. He is the recipient of various grants and awards from the National Cancer Institute; a K23 award and 3 translational research grants for the development of new drugs. Dr Niesvizky regularly presents at annual meetings such as ASH and ASCO, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

Faculty

Rafat Abonour

MD
Professor of Medicine
Sylvester Myeloma Institute , University of Miami

Rafat Abonour, MD, is Professor of Clinical Medicine and Associate Director of Clinical Affairs in the Division of Myeloma at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. A nationally and internationally recognized hematologist-oncologist, his clinical practice and translational research focus on multiple myeloma, smoldering multiple myeloma, light chain (AL) amyloidosis, Waldenström macroglobulinemia, extramedullary disease, minimal residual disease (MRD) monitoring, and novel T-cell redirection immunotherapies, including CAR T-cell therapies and bispecific antibodies.

Before joining the University of Miami, Dr. Abonour spent three decades at Indiana University School of Medicine, where he held the Harry and Edith Gladstein Endowed Chair in Cancer Research and directed the Multiple Myeloma, Waldenström's Disease, and Amyloidosis Program as well as the Bone Marrow and Stem Cell Transplantation Program.
He is a member of the International Myeloma Working Group (IMWG), and a past Chair of the American Society of Hematology (ASH) Plasma Cell Scientific Committee and Track Leader for the ASCO Myeloma Scientific and Educational Committees. He is also the founder of Miles for Myeloma, an endurance fundraising initiative that has raised over $11 million for myeloma research.

Faculty

Melissa Alsina

MD
Head, Myeloma Section
H.Lee Moffitt Cancer Center

Dr. Melissa Alsina is Professor of Medicine in the Blood and Marrow Transplant Program at Moffitt Cancer Center and Head of the Multiple Myeloma Transplant Program. A specialist in multiple myeloma and bone marrow transplantation, Dr. Alsina focuses much of her clinical research on novel therapies in myeloma, including immunotherapies. A graduate of the University of Puerto Rico School of Medicine, Dr. Alsina completed her residency in Medicine at San Juan Veterans Administration Hospital, followed by a fellowship in Hematology at San Juan City Hospital in Puerto Rico and Medical Oncology/Hematology at the University of Texas Health Science Center at San Antonio, Texas. Before coming to Moffitt in 2000, Dr. Alsina was an Assistant Professor of Medicine at the South Texas Veterans Health Care System in San Antonio. She was also co-director of the Myeloma Bone Disease Program Clinic at the UT Health Science Center at San Antonio, where she served on the faculty from 1995-1999. Dr. Alsina is a member of several professional organizations, including the International Myeloma Society and The American Society of Hematology, and has been a member of the NCCN myeloma panel and the NCI Myeloma Steering Committee. She is also very active in organizing educational programs for myeloma patients and their families.

Faculty

Benjamin Diamond

MD
Assistant Professor
University of Miami

Dr. Diamond specializes in the treatment of plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. His research interests include the genomics of multiple myeloma, blood-based disease assessment, and minimal residual disease (MRD) in clinical decision-making. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow. He now serves as co-Leader of the Myeloma Computational and Translational Laboratory at Sylvester Comprehensive Cancer Center in the Division of Myeloma at the University of Miami’s Sylvester Comprehensive Cancer Center. Current projects focus on resistance mechanims to novel immunotherapies and whole genome sequencing of circulating tumor DNA.

Faculty

Adriana Rossi

MD
Director of Myeloma CAR-T and Stem Cell Transplant Clinical Program
Mount Sinai School of Medicine

Adriana Rossi is the Director of Myeloma CAR-T and Stem Cell Transplant Clinical Program at the Center of Excellence for Multiple Myeloma at the Mount Sinai School of Medicine. Dr Rossi has extensive experience in treating patients with multiple myeloma and related diseases, with special focus on cellular therapy.

Faculty

Ken Shain

Back to top